Account Info
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Do not show
Hide blank lines
30.41% 1.55B 24.44% 1.19B -- 956.7M
Operating income
30.41% 1.55B 24.44% 1.19B 956.7M
Cost of sales
-8.04% -198.15M -14.64% -183.41M -- -159.99M
Operating expenses
-8.04% -198.15M -14.64% -183.41M -159.99M
Gross profit
34.48% 1.35B 26.40% 1.01B 796.71M
Selling expenses
-118.54% -346.21M -68.91% -158.42M -- -93.79M
Administrative expenses
-119.07% -72.27M -14.38% -32.99M -- -28.85M
Research and development expenses
-86.49% -24.95M -17.38% -13.38M -- -11.4M
Impairment and provision
-113.15% -326K 342.09% 2.48M -- -1.02M
-Other impairment is provision
-113.15% -326K 342.09% 2.48M -- -1.02M
Special items of operating profit
-63.00% 62.35M 998.29% 168.49M -- 15.34M
Operating profit
-0.03% 972.92M 43.76% 973.24M 677M
Earning before tax
-0.03% 972.92M 43.76% 973.24M 677M
1.34% -144.79M -44.14% -146.76M -- -101.82M
After-tax profit from continuing operations
0.20% 828.13M 43.69% 826.49M 575.18M
Earning after tax
0.20% 828.13M 43.69% 826.49M 575.18M
Minority profit
-- -- -99.85% 35K -- 22.92M
Profit attributable to shareholders
0.20% 828.13M 49.65% 826.45M 552.26M
Basic earnings per share
0.00% 0.83 50.91% 0.83 0.55
Diluted earnings per share
0.00% 0.83 50.91% 0.83 0.55
Currency Unit
Accounting Standards
Audit Opinions
Unqualified OpinionUnqualified OpinionUnqualified Opinion
Ernst & YoungErnst & YoungErnst & Young

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Juzi Biotech Holdings Co., Ltd. is a Chinese investment holding company. Through its subsidiaries, the company is mainly engaged in the R&D, production and sale of beauty and health products based on bioactive materials. The company's main products include functional skincare products and medical dressings, and the key bioactive ingredient in its products is recombinant collagen. The company also develops and produces rare functional foods based on ginsenoside technology. The company mainly conducts its business in the domestic market.
CEO: Jianya Yan
Market: Hong Kong motherboard
Listing Date: 11/04/2022
Hot List
SymbolLatest price%Chg